The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet).
Cycle control and tolerance were studied in a group of 55 female volunteers, who took during 42 consecutive days a modern low-dose oral contraceptive: gestodene 75 micrograms/ethinylestradiol 30 micrograms (Minulet). During these 42 days, 96% of the women experienced no breakthrough bleeding and 81% of the women experienced no spotting or breakthrough bleeding. When the findings of this study are compared with the findings of an earlier study with also a seven-week cycle but with other oral contraceptives, it can be concluded that Minulet offered an excellent cycle control.
Kornaat
H
H
Wyeth Laboratories, Hoofddorp, The Netherlands.
Geerdink
M H
MH
Klitsie
J W
JW
D000293:Adolescent; D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology / Q000592:standards*; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000494:pharmacology / Q000592:standards*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D009652:Norpregnenes / Q000494:pharmacology / Q000592:standards*; D010349:Patient Compliance; D013997:Time Factors
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; C055368:Femovan; D004997:Ethinyl Estradiol